This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Bioarctic Neuroscience Ab, Eisai R&d Management Co., Ltd.. Active years: 2017.
Company Filing History:
1 out of 16 
1 out of 530 
Years Active: 2017
Title: Hanna Laudon: Innovator in Alzheimer's Disease Research
Introduction
Hanna Laudon is a notable inventor based in Nacka, Sweden. He has made significant contributions to the field of neuroscience, particularly in the study and treatment of Alzheimer's disease. His innovative work focuses on the development of antibodies that target amyloid beta protofibrils, which are implicated in the progression of Alzheimer's.
Latest Patents
Hanna Laudon holds 1 patent related to his groundbreaking research. The patent, titled "Aβ protofibril binding antibodies," pertains to antibodies that bind to amyloid beta protofibrils. This invention has potential applications in the therapy and prophylactic treatment of Alzheimer's disease and other disorders associated with amyloid beta protein aggregation. Additionally, it may aid in the diagnosis of such diseases and the monitoring of disease progression. The invention also has implications for veterinary use.
Career Highlights
Throughout his career, Hanna has worked with prominent companies in the neuroscience sector. Notably, he has been associated with Bioarctic Neuroscience AB and Eisai R&D Management Co., Ltd. His work in these organizations has furthered the understanding and treatment of neurodegenerative diseases.
Collaborations
Hanna has collaborated with several professionals in his field, including Charlotte Nerelius and Jessica Sigvardson. These partnerships have contributed to the advancement of research and development in Alzheimer's disease therapies.
Conclusion
Hanna Laudon's innovative contributions to Alzheimer's research through his patent on amyloid beta protofibril binding antibodies highlight his commitment to addressing critical health challenges. His work continues to pave the way for new therapeutic approaches in the fight against neurodegenerative diseases.